{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '6.5.1.5.', 'Disallowed Medications and Therapies', 'The following concurrent medications are prohibited during the study:', 'Rituximab', 'Chronic PE/PP therapy', 'Chronic IVIg therapy', 'Eculizumab (or other complement-inhibitors)', 'Patient-use of rituximab or eculizumab (or other complement inhibitors) at any point during the', 'study will result in the patient being discontinued from the study.', '6.5.2.', 'Rescue Therapy', \"Rescue therapy (eg, high-dose corticosteroid, PE/PP, or IVIg) will be allowed when a patient's\", 'health would be in jeopardy if rescue therapy was not administered (eg, emergent situations) or,', 'if a patient experiences Clinical Deterioration as defined in this protocol. The rescue therapy', 'used for a particular patient will be at the discretion of the Investigator. The date and time of', 'rescue medication administration as well as the name and dosage regimen of the rescue', 'medication will be recorded.', 'Should a patient require rescue therapy, every effort should be made to notify the Sponsor within', '24 hours.', '6.6.', 'Intervention After the End of the Study', 'Patients will return to the care of their treating physician at the completion of study participation.', 'Page 49 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '7.', 'DISCONTINUATION OF STUDY INTERVENTION AND', 'PATIENT DISCONTINUATION/WITHDRAWAI', '7.1.', 'Discontinuation of Study Intervention', 'A patient may withdraw from the study at any time at his/her own request, or may be withdrawn', 'at any time at the discretion of the Investigator for safety, behavioral, compliance, or', 'administrative reasons. If a patient discontinues treatment from the study, the Investigator will', 'attempt to perform (if the patient agrees) assessments specified for the ET Visit, or if not', 'possible, a follow-up phone call to be conducted 8 weeks after the last dose of study drug has', 'been administered (SoA, Section 1.3). Attempts should also be made to follow all patients for', 'safety for a total of 8 weeks from the day the last dose of study drug is administered. The', 'Sponsor and site monitor will be notified as soon as possible. If a patient is withdrawn from the', 'study or withdraws consent no further data will be collected. Patients who withdraw from the', 'study will not be replaced.', 'Patients should be discontinued from study drug if any of the following occur during the study:', '1. Serious hypersensitivity reaction (such as bronchospasm with wheezing or requiring', 'ventilator support or symptomatic hypotension, refer to Section 10.5 [Appendix 5]) or', 'serum sickness-like reactions manifesting 1 to 14 days after study drug administration;', '2. Severe uncontrolled infection;', '3. Pregnancy or planned pregnancy; or', '4. Sponsor or Investigator deems it is in the best interest of the patient.', '5. Use of rituximab, eculizumab (or other complement-inhibitors)', 'The Investigator should contact the Medical Monitor prior to discontinuing a patient from study', 'drug. If a patient discontinues from treatment, the patient should be encouraged to return for the', \"ET Visit (SoA, Section 1.3) 8 weeks after the patient's last dose of study drug.\", 'The reason for the treatment discontinuation (ie, patient withdraws consent, patient withdrawal', 'from procedures, physician decision, AE, or other reason specified in eCRF) will be recorded in', 'the eCRF.', 'If a female patient is permanently discontinued from study drug due to pregnancy, the', 'Investigator will make a reasonable attempt to follow-up, in accordance with local laws and', 'regulations, until the outcome of the pregnancy is known (Section 10.4 [Appendix 4]).', 'If the patient withdraws consent for disclosure of future information, the Sponsor may retain and', 'continue to use all data collected before such a withdrawal of consent.', 'If a patient withdraws from the study, the patient may request destruction of any samples taken', 'and not tested, and the Investigator must document this in the site study records as well as inform', 'the site monitor and Sponsor.', '7.2.', 'Lost to Follow Up', 'A patient will be considered lost to follow-up if the patient repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'Page 50 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'The following actions must be taken if a patient fails to return to the clinic for a required study', 'visit:', '1. The site must attempt to contact the patient and reschedule the missed visit as soon as', 'possible and counsel the patient on the importance of maintaining the assigned visit', 'schedule and ascertain whether or not the patient wishes to and/or should continue in the', 'study.', '2. Before a patient is deemed lost to follow up, the Investigator or designee must make', 'every effort to regain contact with the patient (where possible, 3 telephone calls and, if', \"necessary, a certified letter to the patient's last known mailing address or local equivalent\", \"methods). These contact attempts should be documented in the patient's medical record.\", '3. Should the patient continue to be unreachable, the patient will be considered to have', 'withdrawn consent and future missed visits will not be considered protocol deviations.', 'Page 51 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}